Which pre‑ and post‑transplant laboratory tests, imaging studies, and clinical signs indicate successful liver transplantation?

Indicators of Successful Liver Transplantation

Successful liver transplantation is best indicated by normal or near-normal liver function tests (ALT, AST, bilirubin, alkaline phosphatase), stable immunosuppression levels (tacrolimus 4-6 ng/ml after first year), absence of donor-specific antibodies (DSAs), and normal transient elastography values, with clinical stability and absence of vascular or biliary complications on imaging. 1

Pre-Transplant Assessment Parameters

Laboratory Markers

Pre-transplant donor liver assessment should focus on:

• Alkaline phosphatase (AP) is the most predictive donor laboratory marker—elevated donor peak AP significantly predicts graft loss (adjusted HR 1.808) 2
• Donor transaminases (ALT/AST) do NOT predict outcomes—even extremely elevated levels (>1000 U/L) show excellent post-transplant results 2
• Screening for preformed DSAs is mandatory in high-risk recipients (previous transplantation, transfusions, pregnancies) 1

This is a critical pitfall: many centers inappropriately decline livers based on elevated transaminases, but the evidence clearly shows this practice wastes viable organs 2.

Imaging Studies

Pre-transplant imaging assessment includes:

• Doppler ultrasonography for initial vascular and parenchymal evaluation 3
• CT for detecting hemorrhage, abscess, and vascular assessment 3
• Evaluation of donor liver quality through machine perfusion parameters (research setting) 4

Clinical Assessment

Pre-transplant functional capacity assessment should utilize:

• Karnofsky Performance Status (KPS) (strong recommendation, moderate evidence) 5
• Liver Frailty Index (LFI) (strong recommendation, moderate evidence) 5
• Abdominal muscle mass by CT (strong recommendation, moderate evidence) 5
• Cardiopulmonary exercise testing (CPET) when resources permit (weak recommendation) 5

Post-Transplant Success Indicators

Laboratory Monitoring Timeline

Early Period (First Week to 3 Months):

• ALT, AST, and alkaline phosphatase normalize within 3 months in successful transplants 6
• Bilirubin, INR, and albumin return to normal range by 3 months 6
• Platelet counts decrease initially but stabilize (expect 19% reduction at 3 years) 6

Important caveat: Approximately 10% of recipients maintain platelet counts <150×10³/mm³ at 2-3 years, which warrants investigation but doesn't necessarily indicate failure 6.

Long-term (Beyond First Year):

• Tacrolimus levels 4-6 ng/ml (monotherapy) or lower with combination therapy indicate adequate immunosuppression 1
• Normal liver enzymes with substantially lower tacrolimus levels are acceptable in many long-term survivors 1
• Absence of de novo DSAs on monitoring indicates stable graft acceptance 1
• Stable transient elastography values suggest absence of subclinical rejection 1

Critical Warning About Over-Minimization

When managing patients on very low immunosuppression levels, monitor for subclinical rejection through:

• Serial DSA measurements
• Transient elastography
• Surveillance liver biopsies when DSAs are present 1

High mean fluorescence intensity DSAs contraindicate aggressive immunosuppression minimization unless liver biopsy excludes allograft damage 1.

Imaging Indicators of Success

Vascular Patency:

• Patent hepatic artery (most critical—thrombosis causes graft failure) 3, 7
• Normal portal vein flow on Doppler ultrasound 3
• Intact hepatic vein drainage 7

Biliary System:

• Absence of bile leaks (best detected by hepatobiliary scintigraphy) 3
• No biliary strictures (evaluated by MRCP or T-tube cholangiography) 3
• Absence of ischemic-type biliary lesions 4

Parenchymal Assessment:

• Normal liver echogenicity on ultrasound 3
• Absence of fluid collections or abscesses on CT 3

Clinical Signs of Success

• Stable hemodynamics without vasopressor requirements
• Normal synthetic function (coagulation parameters, albumin production)
• Absence of encephalopathy
• Normal bile production (when T-tube present)
• Resolution of pre-transplant complications (ascites, variceal bleeding)

Prognostic Biomarker Combinations

Recent meta-analysis identified superior predictive value with combined biomarkers rather than single markers 8:

• GGT/bilirubin ratio predicts composite outcomes (aHR 4.37)
• ALT+AST+bilirubin+INR combination predicts graft failure or mortality
• Coagulation factor V + ALT predicts graft survival (HR 2.12)
• Coagulation factor V + IGF-1 stratifies patient survival risk (HR 2.97)

These combinations sampled within 15 days post-transplant show significantly better predictive value than single biomarkers 8.

Immunosuppression-Specific Monitoring

Calcineurin Inhibitor Management:

• Minimize CNI exposure through combined regimens, particularly with mTOR inhibitors in cancer recurrence risk 1
• Delay tacrolimus introduction 5 days in patients with pre-existing renal dysfunction, advanced liver failure, hyponatremia, or high BMI 1

mTOR Inhibitor Considerations:

• Everolimus can start day 7 post-transplant
• Sirolimus must be avoided during first month 1
• Strongly recommended for patients with recurrent/de novo non-melanoma skin cancer 1